Company Overview and News

7
GORO / Gold Resource Corp. 8-K (Current Report)

14h sec.gov
goro_Current Folio_8K UNITED STATES
GORO

25
Can Gold Rally Despite A Strong Dollar?

2018-06-15 seekingalpha
Gold is facing what is potentially its toughest test of the year right now. Its attempt at rallying despite a strengthening dollar will test not only the buying power of the gold bulls who believe the metal can rally despite the powerful headwind from gold’s currency component, but also the belief by many investors that higher risk assets offer better value than gold right now. In today’s commentary, we’ll focus on this conflict as I’ll make the case that while gold can make some headway against a strong dollar in the immediate term, a weaker dollar is definitely needed to catalyze a sustainable rally in the intermediate-to-longer term.
GORO PAAS AEM IAU

26
The XAU Teases A Breakout

2018-06-14 seekingalpha
With the price of gold subdued by a strong dollar, most actively traded gold mining stocks are also understandably feeling that same pressure. There are, however, a few conspicuous mining companies which display relative strength in the face of the current weak market for gold. In this report we'll examine these standouts along with the technical condition of the overall mining stock market. My argument is that while gold stocks as a group aren't yet ready to experience a rally, the odds of one later this summer have increased.
GORO PAAS AEM IAU

6
Gold: The Running Away Of The Bulls

2018-06-12 seekingalpha
The moving average that tracks bullish sentiment for gold is at its lowest levels in over 18 months.
RGLD GORO RGL

17
Gold Stocks: A Tale Of 2 Markets

2018-06-11 seekingalpha
Gold mining stocks as measured by the popular averages like the PHLX Gold/Silver Index (XAU) have gone nowhere since April. Yet below the surface, there are signs of promise among individual mining shares. In today’s commentary, we’ll examine this bifurcated market condition and remove the chaff from the wheat to see just where the strength is coming from. We’ll also see that while short-term conditions remain weak for the mining stock group, improvement should become visible by later this summer.
GORO GG IAU GDXJ

47
Royal Gold: A Streamer Bucking The Trend

2018-06-07 seekingalpha
The company has some of the strongest gross margins of all companies in the S&P 500.
SAND SSL GOOS NGD SDDXF OKSWF NGDAF SNXZF NGD RGLD OR GORO OSKGF RGL GSC

20
Do Gold Stocks Have An Excuse To Rally?

2018-06-01 seekingalpha
While gold’s immediate trend remains uncertain in the face of U.S. dollar strength, the metal does have at least one important ally: the gold stocks. As I’ll argue here, recent internal improvements among several actively traded mining shares could serve to stimulate short-term demand for gold. In today’s report, we’ll look at the internal momentum structure for gold stocks and see how much rally potential exists for the XAU index in June.
GORO GG IAG IAU

20
XAU Strength Critical For Gold Recovery

2018-05-31 seekingalpha
Despite continued currency pressures, gold is getting a short-term boost from political concerns abroad as well as economic developments at home in the U.S. As we’ll discuss in today’s report, however, gold will need more than just the latest news developments in order to build enough support for a sustainable turnaround. But while dollar strength remains an obstacle, gold has found an ally in the latest rise in the actively traded gold mining stocks which we’ll discuss here.
GORO GG IAG IAU

10
Revival Gold Unveils NI 43-101 Gold Resource at the Beartrack Gold Project in Idaho, USA

2018-05-29 globenewswire
TORONTO, May 29, 2018 (GLOBE NEWSWIRE) -- Revival Gold Inc. (TSX-V:RVG) (OTCQB:RVLGF) (“Revival Gold” or the "Company"), a growth-focused gold exploration and development company, is pleased to announce a NI 43-101 mineral resource estimate (“Mineral Resource”) for the past producing Beartrack Gold Project (“Beartrack”) located in Lemhi County, Idaho.
MALRY GORO MALRF MIN

6
Gold: Are The Lows In?

2018-05-27 seekingalpha
In what has been a tricky start to the year for most asset classes, Gold (GLD) has acted as a haven to hide from the turbulence. While the metal hasn't outperformed the market indices with its 1% year to date return, it has provided a smoother sleep schedule with its lower relative volatility. The recent pullback in gold has sent it back down to its 20-month moving average and to just below its previous resistance level ($1,300/oz).
TPWRF GORO GCM GCM.WT.A TPRFF

6
Gold Resource Corporation Receives Final Permit and Board Approval for Isabella Pearl Gold Project, Mineral County, Nevada

2018-05-15 globenewswire
COLORADO SPRINGS, May 15, 2018 (GLOBE NEWSWIRE) -- Gold Resource Corporation (NYSE American: GORO) (the “Company”) today announced it has been granted a positive Record of Decision (ROD) on the Environmental Assessment (EA) for the Isabella Pearl open pit heap leach gold project (Project) located in Mineral County, Nevada. This final permit, along with approval from the Company’s Board of Directors to move the Project into production, mark a major milestone for the Company’s Nevada Mining Unit.
GORO

6
Gold Resource: A Clear Winner

2018-05-07 seekingalpha
Gold Resource reported earnings of $0.10 per share on revenue of $32.15 million compared with an earning per share of $0.08, on revenue of $24.34 million in 1Q'17.
GORO

6
Gold Resource Corp.:  Appreciating But Still Substantially Undervalued

2018-05-07 seekingalpha
GORO's stock price is at 52-week highs, but I believe that this still doesn't come close to fully valuing the company.
GORO

6
Gold Resource Corporation 2018 Q1 - Results - Earnings Call Slides

2018-05-03 seekingalpha
The following slide deck was published by Gold Resource Corporation in conjunction with their 2018 Q1 earnings call.
GORO

6
GORO / Gold Resource Corp. 8-K (Current Report)

2018-05-01 sec.gov
goro_Current folio_8K
GORO

Related Articles

CASC: Cascadian Therapeutics Analysis and Research Report

2018-06-22 - Asif

Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...

BAC: Bank of America Corp. Analysis and Research Report

2018-06-22 - Asif

Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

CUSIP: 38068T105